224
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

MDMX/MDM4 is highly expressed and contributes to cell growth and survival in anaplastic large cell lymphoma

, , , , , , , , & show all
Pages 1563-1573 | Received 27 Jul 2020, Accepted 07 Jan 2021, Published online: 11 Feb 2021
 

Abstract

We hypothesized that murine double minute X (MDMX), a negative p53-regulator, may be involved in dysfunctional p53-signaling in anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-positive and ALK-negative, characterized frequently by non-mutated TP53 (wt-p53). By western blot analysis, MDMX was highly expressed in ALK + ALCL and expressed at variable levels in ALK- ALCL cell lines. By immunohistochemistry, high MDMX levels were observed more frequently in ALK + ALCL (36/46; 78%), compared with ALK- ALCL tumors (12/29; 41%) (p < .0018, Mann–Whitney-test). FISH analysis showed MDMX-amplification in 1 of 13 (8%) ALK- ALCL tumors, and low-level MDMX copy gains in 2 of 13 (15%) ALK- ALCL and 3 of 11 (27%) ALK + ALCL tumors. MDMX-pharmacologic inhibition or siRNA-mediated MDMX-silencing were associated with activated p53 signaling, growth inhibition and apoptotic cell death in wt-p53 ALCL cells, providing evidence that targeting MDMX may provide a new therapeutic approach for ALCL patients with wt-p53.

Disclosure statement

The authors declare no conflict of interest.

Additional information

Funding

This study has been partially supported by European Union and Greek national funds (KA 3499, 3703 and 10071) (to ED). It was also supported by grants from Radiumhemmets Forskningsfonder (project 174243), Cancerfonden (19 0277 Pj), Barncancerfonden (PR2019-0133) (to GZR), European Commission and Ministry of National Education and Religious Affairs.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.